@FiercePharma: FDA: The social media guidance puzzle will be complete by July. More | Follow @FiercePharma
@TracyStaton: Hungary joins the club of EU countries approving Novartis' generic version of GSK's blockbuster Advair. News | Follow @TracyStaton
@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI: Allergan rides high on patent backing for key drugs Lumigan and Restasis. Article | Follow @CarlyHFierce
> South Korea's Celltrion won regulatory approval in its home country for Herzuma, its biosimilar version of Roche's ($RHHBY) original breast cancer blockbuster, Herceptin. Report
> Hungary became the latest EU country to approve AirFluSal Forspiro, a generic version of GlaxoSmithKline's ($GSK) blockbuster lung drug Advair made by Novartis' ($NVS) generics unit, Sandoz. Report
> Amarin ($AMRN) said the FDA delayed a decision on a large, late-stage trial of its Vascepa blood-lipid drug; it's the latest obstacle for Amarin in its quest to win approval to market the drug to a broader group of patients. Release | Report
> Novo Nordisk ($NVO) made Fortune's latest list of the 100 best companies to work for, ranked 72nd. Release
> Amgen ($AMGN) teamed up with the gene-sequencing specialist Illumina ($ILMN) to develop a diagnostic test to identify patients for its targeted colon cancer drug Vectibix. Report
> Allergan ($AGN) CEO David Pyott says he's not interested in buying an Irish company to lower his company's corporate taxes. Report
@FierceMedDev: Thermo nabs Chinese approval of $13.6B Life Tech merger. More | Follow @FierceMedDev
@MarkHFierce: Even N.Y. Sen. Chuck Schumer spilled the beans about Carlyle Group's bid for J&J's Ortho Clinical diagnostics arm. Story | Follow @MarkHFierce
@MichaelGFierce: Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Integra finalizes $235M deal for Covidien's surgical products line. News | Follow @EmilyWFierce
@GalenMoore: Bio-Path Holdings is raising $10M for its cancer drug delivery tech. Release | Follow @GalenMoore
> Medtronic must pay Edwards at least $394M in heart valve patent trial defeat. Report
> Illumina will concoct a companion Dx for an Amgen colon cancer drug. Item
> Fallout from Orthofix's Medicare kickback scandal takes down a VA podiatrist. More
Biotech News
@FierceBiotech: Merck clears an FDA panel with its clot-fighting vorapaxar. Story | Follow @FierceBiotech
@JohnCFierce: ICYMI: Roche's dealmakers at pRED will continue their global shopping spree in 2014. More | Follow @JohnCFierce
@DamianFierce: Sarepta still climbing on renewed hopes for eteplirsen. Article | Follow @DamianFierce
@EmilyMFierce: Per the FDA's new stance on antibacterials, here's a list of household products containing triclosan. | Follow @EmilyMFierce
> Amarin endures another FDA delay as Vascepa languishes. More
> J&J shipping out diagnostics biz for $4.2B. Report
> Gentium shareholders cry foul on $1B Jazz deal. News
Pharma Manufacturing News
> Merck recalls all lots of Liptruzet shipped since its May debut. Story
> Former Fresenius employee says he was fired for raising red flags. Article
> Premier supports new FDA compounder oversight plan. Report
> FDA assigns an agent to Europol in its fight against fakes. More
> Sources: Ranbaxy asks the FDA to let it make generic Diovan in U.S. News
> Actavis selling China assets as it exits that country. Item
Vaccines News
> CDC, FDA studies link Merck and GSK rotavirus vaccines to bowel blockages. Story
> BIO and Sanofi are pushing the FDA to tweak its drug shortage rule for vaccines. Story
> A Dendreon consultant has raised $8M for a cancer vaccine startup. Story
> Buzz: Merck and Novartis trying to iron out details of their business unit swap. Story
> AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story
> Astellas and Takeda continue to advance vaccine strategies. Item
And Finally... Rotavirus vaccines from Merck ($MRK) and GlaxoSmithKline ($GSK) may carry a small risk of a type of bowel obstruction, but not enough to change recommendations for their use. Report